FDA Staffers Blast Rosiglitazone at Advisory Panel Meeting
Posted on 13. Jul, 2010 by Dr. Ellis in News and Updates
GAITHERSBURG, Md. (MedPage Today) — The two major FDA critics of rosiglitazone (Avandia) again denounced the diabetes drug during the first day of an advisory committee meeting that will end with a vote on whether the agency should pull it from the market.
Read Full Article…
Possibly Related Blogs
Advisory Panel Faces Tough Call on Rosiglitazone, Experts Say
Posted on 12. Jul, 2010 by Dr. Ellis in News and Updates
WASHINGTON (MedPage Today) — Despite hints that the FDA may be leaning toward pulling rosiglitazone (Avandia) from the market, it’s going to be a tough decision for the advisory committee slated to begin meeting on Tuesday, and things could still go either way, leading endocrinologists predict.
Read Full Article…
